Lineage Cell Therapeutics is a clinical-stage biotechnology company. The company's cell therapy programs in clinical development include: OpRegen?, a retinal pigment epithelium cell replacement therapy in a Phase 1/2a multicenter clinical trial for the treatment of dry age-related macular degeneration with geographic atrophy; OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries; and VAC2, a cancer immunotherapy of antigen-presenting dendritic cells in a Phase 1 clinical trial in non-small cell lung cancer.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.